Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

Nek­tar had the wrong drug at the wrong time.

That was the im­pli­ca­tion from the FDA staff, who in brief­ing doc­u­ments about Nek­tar’s oral opi­oid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.